三月 2026
- Home
- Biocartis
三月 2026的Biocartis市场份额分析
Molecular biomarker results in only 3 hours for fast treatment decisions! THINK IDYLLA™
Biocartis(包含公司地区分支机构)
查看更多网站流量和参与度信息- biocartis.com
Biocartis收入截至 三月 2026为 50M - 75M
Biocartis主要域名产生的收入
3 年中Biocartis主要域名的收入
Biocartis主要域名的收入
Biocartis热门域名的总访问量
了解Biocartis市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Biocartis热门域名的平均访问时长
分析Biocartis参与度指标。
过去 3 个月的平均访问时长
子公司明细
Biocartis热门域名的平均页面浏览量
了解Biocartis如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Biocartis 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Biocartis Group is developing point-of-care breast cancer test on Mar 24th '26.NEW YORK - Belgian diagnostics firm Biocartis said on Tuesday that it has partnered with the Medical College of Wisconsin (MCW) to develop a point-of-care breast cancer test.
三月 24, 2026阅读更多
新闻Biocartis Group partnered with The Medical College of Wisconsin on Mar 24th '26.Itasca, IL, US, 24 March 2026 - Today, Biocartis announced that it has entered into a research collaboration with the Medical College of Wisconsin (MCW) to provide laboratory expertise and archived samples for the development of a rapid, sample-to-answer breast cancer gene signature test.
三月 24, 2026阅读更多
新闻Biocartis Group partnered with Mayo on Jan 12th '26.Itasca, IL, US, 12 January 2026 - Biocartis announced today that it has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to shorten the time to optimal treatment for breast cancer patients.
一月 12, 2026阅读更多
查看 Biocartis 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
